Zimmer POLAR Persona - TKA (EMEA Study)
Launched by ZIMMER, GMBH · Jan 8, 2015
Trial Information
Current as of April 25, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The Zimmer POLAR Persona study is looking at how well a specific type of knee implant, known as the Persona knee implant, works for people who need a total knee replacement due to severe knee pain and disability caused by conditions like osteoarthritis or rheumatoid arthritis. The main goals of this study are to find out how long the implant lasts, how safe it is, and how it improves patients' overall pain, function, and quality of life.
To participate in this study, individuals must be between 18 and 75 years old and have a medical condition that qualifies them for a total knee replacement. This includes those with severe knee pain due to arthritis or other related issues. Participants will undergo scheduled procedures and follow-up evaluations to monitor their progress. It’s important to note that individuals with certain medical conditions, such as infections in the joint or insufficient bone structure, or those who have had previous knee surgeries on the same knee, will not be eligible for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient 18-75 years of age, inclusive.
- * Patient qualifies for primary total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:
- • rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis;
- • collagen disorders and/or avascular necrosis of the femoral condyle;
- • post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy;
- • moderate valgus, varus, or flexion deformities;
- • the salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee.
- • Patient is willing and able to complete scheduled study procedures and follow-up evaluations.
- • Independent of study participation, patient is a candidate for commercially available Zimmer Persona knee implants implanted in accordance with product labeling.
- Exclusion Criteria:
- • Patient is currently participating in any other surgical intervention studies or pain management studies.
- • Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint.
- • Insufficient bone stock on femoral or tibial surfaces.
- • Skeletal immaturity.
- • Neuropathic arthropathy.
- • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb.
- • Stable, painless arthrodesis in a satisfactory functional position.
- • Severe instability secondary to the absence of collateral ligament integrity.
- • Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin.
- • Patient has a known or suspected sensitivity or allergy to one or more of the implant materials.
- • Patient is pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.).
- • Patient has previously received partial or total knee arthroplasty for the ipsilateral knee.
About Zimmer, Gmbh
Zimmer GmbH is a leading global medical device company specializing in innovative solutions for musculoskeletal health. With a commitment to advancing orthopedic and reconstructive surgery, Zimmer GmbH focuses on developing and delivering high-quality products and technologies that enhance patient outcomes and improve the quality of life. The company engages in rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring they meet the highest standards of performance and regulatory compliance. Through collaboration with healthcare professionals and ongoing research, Zimmer GmbH strives to be at the forefront of orthopedic innovation, addressing the evolving needs of patients and medical practitioners worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, , Spain
Zaragoza, , Spain
Clermont Ferrand, , France
Clydebank, , United Kingdom
Wien, , Austria
Montpellier, , France
Braunschweig, , Germany
Heidelberg, , Germany
Delft, , Netherlands
Leeds, Leeds/Uk, United Kingdom
Harrogate, , United Kingdom
Newcastle, , United Kingdom
Patients applied
Trial Officials
Martin Dominkus, MD
Principal Investigator
Orthopädisches Spital Speising, Wien, Austria
Hendrik Verburg, MD
Principal Investigator
Stichting Research Orthopedie & Reinier de Graaf Groep, Delf, Netherlands
Nicholas London, MD
Principal Investigator
Harrogate and District NHS, Harrogate, England
Stéphane Boisgard, MD
Principal Investigator
CHU de Clermont-Ferrand, Clermont-Ferrand, France
François Canovas, Prof
Principal Investigator
Hospital Lapeyronie, Montpellier
Pere Torner, MD
Principal Investigator
Hospital Parc Tauli, Sabadell
Jon Clarke, MD
Principal Investigator
Golden Jubilee National Hospital, Clydebank
David Deehan, Prof
Principal Investigator
Freeman Hospital, Newcastle
Karl Dieter Heller, Prof
Principal Investigator
HEH Braunschweig
Fritz Thorey, Prof
Principal Investigator
Atos Klinik Heidelberg
Fernando Martinez Delgado, MD
Principal Investigator
Hospital Miguel Servet Zaragoza
Hermant Pandit, Prof
Principal Investigator
University of Leeds
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials